Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1544 articles with Gilead Sciences, Inc.
-
Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer
10/15/2019
Mr. Dickinson joined Gilead in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making.
-
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
10/14/2019
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others? -
Clinical Catch-Up: October 7-11
10/14/2019
It was a busy week for clinical trial announcements. Here’s a look. -
As Gilead Sciences and its development partner Galapagos NV eye filing a New Drug Application with the U.S. Food and Drug Administration for its JAK inhibitor filgotinib, the companies’ hopes have been boosted by new 52-week safety data.
-
BioSpace Movers & Shakers, Oct. 11
10/11/2019
Companies strengthen their leadership teams and boards of directors with these appointments. -
Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019
10/10/2019
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes.
-
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis
10/10/2019
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor
-
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
-
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
-
Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan
10/8/2019
Gilead Sciences, Inc. announced that the New Drug Application for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis has been submitted to the Japanese Ministry of Health, Labor and Welfare.
-
Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
10/7/2019
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1
-
AHF Calls on Gilead for Major Price Cut on PrEP Drug Descovy Following FDA Approval
10/5/2019
AIDS Healthcare Foundation (AHF) today is calling on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, for a major price reduction on its HIV/AIDS treatment medication Descovy, the drug company’s fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), for its use now also as pre-exposure prophylaxis or PrEP to prevent HIV acquisition in uninfected individuals.
-
Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019
10/4/2019
Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP™
-
The only other drug currently approved in the U.S. for HIV PrEP is Gilead’s Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).
-
U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)
10/3/2019
Descovy Demonstrated Non-inferior Efficacy and an Improved Bone and Renal Safety Profile Compared with Truvada® in People at Risk for Sexually Acquired HIV Infection in a Global Phase 3 Trial
-
FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
10/3/2019
The U.S. Food and Drug Administration approved Descovy in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.
-
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
-
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
-
Gilead Sciences and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA)
9/9/2019
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London.
-
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology
9/9/2019
DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc. to DURECT under the license agreement between the companies.